Back to Search
MARK CLEMONS, DMD
DMD
General Practice Dentistry
NPI: 1164517553Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
VA0401005863(VA)
Research & Publications (20)
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
PMID 19424729·Support Care Cancer·2010
8-other
Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
PMID 19364633·J Pain Symptom Manage·2009
8-other
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
PMID 19266291·Clin Exp Metastasis·2009
8-other
Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
PMID 19443366·Anticancer Res·2009
8-other
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases.
PMID 19635661·Eur J Cancer·2009
4-observational
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
PMID 19672422·Curr Oncol·2009
8-other
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
PMID 19360288·Oncol Rep·2009
8-other
Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
PMID 19307138·Crit Rev Oncol Hematol·2009
6-review
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
PMID 19398598·J Clin Pathol·2009
3-trial
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
PMID 19551499·Breast Cancer Res Treat·2009
8-other
Prevention and management of bone metastases in lung cancer: a review.
PMID 19179905·J Thorac Oncol·2009
6-review
Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.
PMID 19596950·Anticancer Res·2009
8-other
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.
PMID 19097882·Eur J Cancer·2009
8-other
Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer.
PMID 19433392·Clin Breast Cancer·2009
8-other
Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer.
PMID 18941910·Clin Exp Metastasis·2009
8-other
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
PMID 19299237·Clin Breast Cancer·2009
4-observational
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
PMID 19299408·Ann Oncol·2009
3-trial
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
PMID 17473981·Breast Cancer Res Treat·2008
3-trial
A primer of bone metastases management in breast cancer patients.
PMID 18231649·Curr Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 301 W. GRAYSON ST.
GALAX, VA 24333 - Phone
- (276) 236-6321
Quick Facts
- NPI
- 1164517553
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile